Reading REGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track REGN free→Reading REGN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track REGN free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and management's recent track record has been steady, with a capital-friendly approach. Earnings quality is neutral, and risk is moderate, while the sector backdrop presents a headwind. Peer multiples imply a price about 18% above where it trades (it looks cheap on this basis); the read is fair. The outlook hinges on guidance changes and sector trends, particularly the performance of key Healthcare bellwethers. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $614.73. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $615 REGN trades at 13× p/e, below its 17× p/e peer median. Our $739 fair value sits above the price; high confidence. Analysts: $641–$995. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 17% below a flat-multiple fair value, below our forecast of about 7%. This describes what's priced in, not a forecast of the move.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.13x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $10.88 → $10.85 (-0.3% / 30d). 9 raised, 11 cut, 23 covering analysts.
0 upgrades, 2 downgrades / 30d, 7 maintained. 72% of analysts rate Buy.
8 PT revisions / 30d. Avg target 20.9% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$109.
How much price usually moves either way.
On a bad day, this stock has moved -$309.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,596.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Strong Dupixent sales growth is key to overall revenue and market confidence.
Confirms:Dupixent global net sales growth exceeds 30% year over year in Q2 2026.
Disproves:Dupixent sales growth falls below 20% year over year in Q2 2026.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
New trials enhance product pipeline and growth potential.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$641.00 – $995.00 (median $821.50) · 18 analysts · as of 2026-05-19
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
REGN Regeneron Pharmaceuticals | Above typical Show detailsSector percentile: 87 of 100 | fair | moderate |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
1 material management or governance event in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Regeneron aims to maintain its GAAP gross margin on net product sales within the guided range.
Regeneron is focused on managing its capital expenditures within the guided range.
Regeneron aims to control its GAAP effective tax rate within the guided range.
Why it matters: Keeping gross margin guidance shows the company can control costs. This is important for making money.
Confirms:Management says GAAP gross margin guidance is the same or better.
Disproves:Management lowers GAAP gross margin guidance below where it is now.
Why it matters: Good results could help fianlimab treat melanoma. This may make investors more confident.
Confirms:Regeneron shares good results from the Phase 3 fianlimab study for skin cancer.
Disproves:Results from the Phase 3 fianlimab study are not good or unclear.
Why it matters: A drop in sector revenue growth could signal broader challenges in the healthcare market.
Confirms:Sector revenue growth falls below its median rate.
Disproves:Sector revenue growth remains above its median rate.
Why it matters: Good management of capital spending can help financial health and support growth.
Confirms:Management says they are keeping spending on track and within budget.
Disproves:Management says spending is much more than they planned.
Why it matters: Approval could help Regeneron offer more treatments and make more money.
Confirms:FDA approves the NDA for cemdisiran in myasthenia gravis in the fourth quarter of 2026.
Disproves:FDA rejects or delays the NDA for cemdisiran.
Why it matters: A quick approval could increase EYLEA HD sales. It may improve market position.
Confirms:FDA approval of the EYLEA HD pre-filled syringe application by the end of Q2 2026.
Disproves:FDA delays or rejects the application for the EYLEA HD pre-filled syringe.
Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2026 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $102 million on a pre-tax basis. This charge primarily relates to premium on equity securiti…
The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Q4 2025 IPR&D Charge . The Company currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the fourth quarter 2025 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $19 million on a pre-tax basis. This acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share for the fourth quarter…
The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.